The Sansure® Human Papillomavirus DNA Diagnostic Kit offers excellent reproducibility performance for the detection of high‐risk HPV
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29961 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Jean-Luc Prétet und 9 weiteren Autor:innen. Beteiligte Einrichtung: Université de Franche-Comté, CNRS, Chrono-Environnement, Besançon, France. Hauptthemen laut MEDLINE: Papillomavirus Infections, Reagent Kits, Diagnostic, DNA, Viral, Papillomaviridae. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sansure, Research and Innovation of the European Commission.
Abstract (Originalsprache)
Cervical cancer screening is a cornerstone of cervical cancer elimination. Detection of high‐risk human papillomavirus (hrHPV) is recommended as the first step in screening provided that the assay used has been adequately validated. The Sansure® Human Papillomavirus DNA Diagnostic Kit is a new assay designed to detect HPV16, HPV18 and 13 other HPV in aggregate. The study aimed to evaluate the intra‐ and interlaboratory reproducibility of the assay according to international guidelines. Five hundred and fifty cervical residual cell samples from women attending cervical cancer screening were selected from the biobank of the HPV National Reference Centre in Belgium and used in this study. After DNA extraction, HPV was tested using the Sansure® Human Papillomavirus DNA Diagnostic Kit. The lower 95% confidence limit around the general reproducibility of this assay should be greater than or equal to 87%, with κ ≥ 0.50. Five hundred and thirty‐three samples had valid results. The Sansure® Human Papillomavirus DNA Diagnostic Kit demonstrated an excellent intra‐laboratory reproducibility of 93.8% (95% confidence interval [CI]: 91.4–95.7, κ = 0.85). The interlaboratory reproducibility was 93.4 (95% CI: 91.0–95.4, κ = 0.84). Intra and interlaboratory reproducibility were also excellent at the genotype level. Excluding HPV53 single infection samples from the analyses also resulted in excellent agreement. These data show that the Sansure® Human Papillomavirus DNA Diagnostic Kit is highly reproducible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Franche-Comté, CNRS, Chrono-Environnement, Besançon, France.
- CHU Besançon, Centre National de Référence Papillomavirus, Besançon, France.
- Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.
- Algemeen Medisch Laboratorium, Antwerp, Belgium.
- Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium.
ORCID-Profile: Jean-Luc Prétet, Quentin Lepiller, Marc Arbyn
Förderung
- Sansure
- Research and Innovation of the European Commission
Zitieren
APA
Prétet, J. L., Baraquin, A., Chung, P. Y. J., Puget, L., Dhillon, S. K., Tkachenka, Y., Jacquot, K., Lepiller, Q., Broeck, D. V., & Arbyn, M. (2024). The Sansure® Human Papillomavirus DNA Diagnostic Kit offers excellent reproducibility performance for the detection of high‐risk HPV. Journal of Medical Virology. https://doi.org/10.1002/jmv.29961
Vancouver
Prétet JL, Baraquin A, Chung PYJ, Puget L, Dhillon SK, Tkachenka Y, et al. The Sansure® Human Papillomavirus DNA Diagnostic Kit offers excellent reproducibility performance for the detection of high‐risk HPV. Journal of Medical Virology. 2024. doi:10.1002/jmv.29961
BibTeX
@article{Prtet2024,
author = {Prétet, Jean-Luc and Baraquin, Alice and Chung, Pui Yan Jenny and Puget, Line and Dhillon, Sharonjit K and Tkachenka, Yuliya and Jacquot, Killian and Lepiller, Quentin and Broeck, Davy Vanden and Arbyn, Marc},
title = {The Sansure® Human Papillomavirus DNA Diagnostic Kit offers excellent reproducibility performance for the detection of high‐risk HPV},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29961}
}
EUVIMED